GHK-Cu

Based on available research evidence, GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is being investigated for several therapeutic applications, though the clinical evidence base remains limited:

Wound Healing and Skin Applications

The primary clinical focus appears to be on topical wound healing applications. There is currently one Phase 2 clinical trial (NCT07437586) recruiting patients to evaluate topical GHK-Cu gel for acute skin wound healing. Research suggests the compound may promote wound healing through multiple mechanisms, including glucose regulation and addressing hypoxia in infected diabetic wounds, though specific clinical outcomes from controlled trials are not yet available.

A completed Phase 4 trial (NCT05932732) examined facial skin quality and hydration effects, though this appears to have been conducted in combination with other treatments (HydraFacial procedures), making it difficult to isolate GHK-Cu's specific contributions.

Anti-Aging and Longevity Research

Preclinical studies suggest potential anti-aging applications, with research in animal models (middle-aged mice) showing behavioral improvements and effects on hippocampal aging programs when administered intraperitoneally or intranasally. Studies in C. elegans indicate the compound may delay aging through mitochondrial function regulation and activation of specific cellular pathways (DAF-16/SKN-1).

Radiation-Induced Skin Injury

Research has explored GHK-Cu's potential in treating radiation-induced skin injury through injectable hydrogel formulations designed for sequential antioxidant and tissue regeneration therapy, though clinical validation is pending.

Bone and Tissue Regeneration

Laboratory studies have investigated GHK-Cu's role in osteogenic-angiogenic coupling responses, suggesting potential applications in bone and tissue regeneration, though clinical trials in this area have not been identified.

Important Limitations: The clinical evidence for GHK-Cu remains largely preclinical, with most studies conducted in laboratory settings or animal models. While the compound shows promise across multiple therapeutic areas, robust human clinical trial data demonstrating safety and efficacy for specific conditions is currently limited. Patients should consult healthcare providers before considering GHK-Cu for any medical condition.